InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-12.4%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Schwab Gisela, Président, Développement des Produits et Affaires Médicales. Insider active across 1 company, notably Exelixis, INC.. Cumulatively, 8 reports have been recorded. History available since 13 May 2021. The latest transaction was filed on 26 July 2021 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Declarations8 total
40,000 shares@ US$4.2016.8% of flowCommon StockSEC:0000939767-21-000074
40,000 shares@ US$4.200.0012% mcap16.8% of flowCommon StockSEC:0000939767-21-000074:0
35,000 shares@ US$4.2014.7% of flowCommon StockSEC:0000939767-21-000073
35,000 shares@ US$4.200.0011% mcap14.7% of flowCommon StockSEC:0000939767-21-000073:0
100,000 shares@ US$1.9018.5% of flowCommon StockSEC:0000939767-21-000050
100,000 shares@ US$1.900.0014% mcap18.5% of flowCommon StockSEC:0000939767-21-000050:0
65,498 sharesCommon StockSEC:0000939767-16-000142:0
25,232 sharesCommon StockSEC:0000939767-16-000142:1
8 of 8 declarations
About Schwab Gisela
Gisela Schwab is the President of Product Development and Medical Affairs at Exelixis, Inc. She is responsible for product development strategy and medical innovation. Gisela plays a key role in the strategic direction of Exelixis, a company specializing in biotechnology.
